Effectiveness of sparfloxacin for Chlamydia pneumoniae infection in patients with bronchial asthma

Takahiko Horiguchi, Soichi Tachikawa, Junichi Kasahara

Research output: Contribution to journalArticlepeer-review


In order to evaluate the effectiveness of sparfloxacin (SPFX), a synthetic new quinolone antibacterial agent 26 patients with bronchial asthma, in whom Chlamydia (C.) pneumoniae IgG and IgA antibody titers (ID) were elevated more than 1.01 were studied. They were divided at random into two groups: SPFX administration group (14 patients) and non-administration group (12 patients). In SPFX administration group, 200mg/day of this drug was administered for 3 weeks. In the SPFX administration group, a significant improvement in serum CRP, and significant decreases in peripheral eosinophil count, serum ECP, and sputum ECP were observed. Furthermore, there were also noted significant decreases in frequency of asthmatic attacks in frecuency of inhalation of β2 stimulant, and a significant increse in PEE in the morning. Thus, it was suggested that administration of SPFX was effective for patients with bronchial asthma accompanying persistent C. pneumoniae infection.

Original languageEnglish
Pages (from-to)453-459
Number of pages7
JournalJapanese Journal of Chest Diseases
Issue number5
Publication statusPublished - 18-06-2002

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Effectiveness of sparfloxacin for Chlamydia pneumoniae infection in patients with bronchial asthma'. Together they form a unique fingerprint.

Cite this